Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

China will adjust tariffs on imported U.S. products from 12:01 p.m. Wednesday, the Customs Tariff Commission of the State Council announced on Tuesday.

Listed companies with main IVD business in China have completed the disclosure of their financial results in the first half of 2023.

Quest Diagnostics Inc (DGX, Financial), a leading provider of diagnostic information services, released its Q3 2023 earnings report on October 24, 2023. Despite a decrease in overall revenues, the company's base business revenues showed growth, largely due to strength in their physician and hospital channels.

On October 24, 2023, Danaher Corp (DHR, Financial) released its Q3 2023 earnings report, revealing a net earnings of $1.1 billion, or $1.51 per diluted common share.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

Foundation Medicine announced on Monday that it is expanding its partnership with Sequanta Technologies to provide its genomic profiling tests for research and oncology therapy development in China.

Switzerland's Roche (ROG.S) has agreed to pay an initial $7.1 billion to Roivant (ROIV.O) and Pfizer (PFE.N) for rights to a new inflammatory bowel disease drug, as it expands into new fields to offset falling oncology sales.

Roswell Park Cancer Center said this week that Agilent Technologies has licensed its blood cancer assay, PanHeme.

The World Health Organization on Thursday announced that it has published a fourth edition of its essential diagnostics list (EDL) adding tests for the hepatitis E virus and recommendations related to access to personal-use glucose monitoring devices.

Thermo Fisher Scientific and Boehringer Ingelheim said on Thursday that they have partnered to develop companion diagnostic tests to help identify patients with non-small cell lung cancer (NSCLC) with specific mutations who may benefit from emerging targeted therapies.

Group sales grow by 1% at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarter.